"Carmustine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
| Descriptor ID |
D002330
|
| MeSH Number(s) |
D02.654.692.247 D02.948.594.247
|
| Concept/Terms |
Carmustine- Carmustine
- BCNU
- N,N'-Bis(2-Chloroethyl)-N-Nitrosourea
- 1,3-Bis(2-Chloroethyl)-1-Nitrosourea
- FIVB
|
Below are MeSH descriptors whose meaning is more general than "Carmustine".
Below are MeSH descriptors whose meaning is more specific than "Carmustine".
This graph shows the total number of publications written about "Carmustine" by people in this website by year, and whether "Carmustine" was a major or minor topic of these publications.
![]()
To see the data from this visualization as text,
click here.
Below are the most recent publications written about "Carmustine" by people in Profiles.
-
Thamilselvan V, Menon M, Stein GS, Valeriote F, Thamilselvan S. Combination of Carmustine and Selenite Inhibits EGFR Mediated Growth Signaling in Androgen-Independent Prostate Cancer Cells. J Cell Biochem. 2017 12; 118(12):4331-4340.
-
Chakravarti A, Chakladar A, Delaney MA, Latham DE, Loeffler JS. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res. 2002 Aug 01; 62(15):4307-15.
-
Recht L, Fram RJ, Strauss G, Fitzgerald TJ, Liepman M, Lew R, Kadish S, Sherman D, Wilson J, Greenberger J, et al. Preirradiation chemotherapy of supratentorial malignant primary brain tumors with intracarotid cis-platinum (CDDP) and i.v. BCNU. A phase II trial. Am J Clin Oncol. 1990 Apr; 13(2):125-31.
-
Antman K, Eder JP, Elias A, Shea T, Peters WP, Andersen J, Schryber S, Henner WD, Finberg R, Wilmore D, et al. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience. Cancer Treat Rep. 1987 Feb; 71(2):119-25.
-
Peters WP, Eder JP, Henner WD, Schryber S, Wilmore D, Finberg R, Schoenfeld D, Bast R, Gargone B, Antman K, et al. High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial. J Clin Oncol. 1986 May; 4(5):646-54.
-
Abelson HT, Karlan D, Penman S. A comparison of the effects of alkylating agents 1,3-bis(2-chloroethyl)-1-nitrosourea, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea and nitrogen mustard on nuclear RNA synthesis and processing. Biochim Biophys Acta. 1974 May 31; 349(3):389-401.